Ken Griffin Genenta Science S.P.A. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
Shares
1 transactions
Others Institutions Holding GNTA
# of Institutions
6Shares Held
537KCall Options Held
0Put Options Held
0-
Allianz Se Munich, 2M234KShares$1.02 Million0.02% of portfolio
-
Al Ti Global, Inc. New York, NY200KShares$875,2580.02% of portfolio
-
Algebris (Uk) LTD London, X0100KShares$437,0000.08% of portfolio
-
Morgan Stanley New York, NY3.4KShares$14,8580.0% of portfolio
-
Ubs Group Ag91Shares$3970.0% of portfolio
About Genenta Science S.p.A.
- Ticker GNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,216,900
- Market Cap $79.6M
- Description
- Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated...